GSK’s reduced dependence on "white pills" makes pharma performance hard to swallow
This article was originally published in Scrip
Executive Summary
The "returns-based" reengineering of GlaxoSmithKline's business continues to take its toll on the company's bottom line as the company reported its full year results for 2010. Legal charges and restructuring costs took nearly 75% out of the earnings per share across the whole company, and pharmaceutical revenues were substantially down in the US and European markets.